Nowadays, the expansion and overlap of various demyelinating diseases, namely MS, NMOSD, ADEM (Acute Disseminating Encephalomyelitis), MOG-Demyelinating (Myelin Oligodendrocyte Glycoprotein-Demyelinating) disease, Optic Neuritis, etc., make the need for specific biomarkers more urgent than ever before, as noted in our previous critical review [39] and in this works of other researchers [40]. This evidence concerns the gene OMG and acute disseminated encephalomyelitis.